Form D · Biotechnology
NUVIANT MEDICAL INC.
Dallas, TX · CIK 0001638919
Offering snapshot reported Jun 16, 2016 · SEC filing
- Reported sold
- Yet to sell Offering amount: $825K
- Investors reported
- 0 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- Yet to occur As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 16, 2016 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Apr 30, 2015 | Initial | $143,000 | No comparison | 93 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $75K (estimated)
- Finders' fees
- $0
- Form D file number
- 021-265200
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Palladium Capital Advisors | 129400 | Abraham Biderman · CRD 2032813 |
Source: Form D, filed Jun 16, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Brian Blischak | Director, Executive |
| Ronald Conquest | Director |
| David B Kaysen | Director |
| Christopher R Miller | Executive |
| William Rosellini | Director, Executive |
| Alexander Ruckdaeschel | Director |
| Hartnut Spitaels | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3824 Cedar Springs Rd. #419
Dallas, TX, 75219
Dallas, TX, 75219